Dissociations between changes in myocardial cyclic adenosine monophosphate and contractility

Area of Science:

• Cardiovascular Physiology
• Biochemistry

Background:

• Adenosine 3':5'-cyclic monophosphate (cyclic AMP) is a key intracellular second messenger.
• Its role in regulating cardiac contractility is well-established, often mediated by protein kinase A.
• However, the precise relationship between cyclic AMP levels and contractility under various stimuli requires further investigation.

Purpose of the Study:

• To investigate the relationship between myocardial cyclic AMP concentration and cardiac contractility in guinea pig and rat hearts.
• To determine if changes in cyclic AMP levels correlate with altered cardiac contractility when stimulated by papaverine or glucagon.

Main Methods:

• Isolated perfused guinea pig and rat hearts were used to study myocardial cyclic AMP levels and contractility.
• Papaverine (a phosphodiesterase inhibitor) and glucagon were administered as stimuli.
• Adenylate cyclase activity was measured in myocardial cell preparations.

Main Results:

• Papaverine increased cyclic AMP levels in guinea pig hearts but did not affect contractility.
• Glucagon increased cyclic AMP levels and adenylate cyclase activity in rat hearts but not in guinea pig hearts.
• Despite these biochemical differences, glucagon produced similar positive inotropic effects in both species.

Conclusions:

• Changes in cardiac contractility were dissociated from stimulated adenylate cyclase activity and increased myocardial cyclic AMP levels.
• The positive inotropic effects of glucagon were independent of significant increases in cyclic AMP in guinea pig hearts.
• These findings suggest complex regulatory mechanisms of cardiac contractility beyond direct cyclic AMP elevation.